GlassScriptPhysician profile
Aneesha Ananthula
NPI 1336593557
$8,038.12
in general payments reported to CMS, 2019-2025
46 companies · $3,501 in 2025
The $3,501 reported for 2025 was more than what a typical Hematology (Internal Medicine) provider received nationally (typical 2025 total: $1,177).
See the full distribution for Hematology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.32 · 2022: $236 · 2023: $1,318 · 2024: $2,970 · 2025: $3,501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,211 · Consulting Fee: $2,680 · Long Term Medical Supply Or Device Loan: $897.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,211.09 |
| Consulting Fee | $2,680.00 |
| Long Term Medical Supply Or Device Loan | $897.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,821.81 | 2020-2025 | Enhertu, Calquence, Lynparza |
| Novartis Pharmaceuticals Corporation | $1,161.62 | 2023-2025 | |
| Celgene Corporation | $480.03 | 2023-2024 | Reblozyl, Pomalyst, Onureg |
| Pfizer INC. | $474.84 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $271.14 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $215.48 | 2022-2025 | Darzalex, Imbruvica, Talvey |
| Bayer Healthcare Pharmaceuticals INC. | $199.85 | 2022-2024 | |
| Seagen INC. | $183.10 | 2023 | Padcev, Tukysa |
| Takeda Pharmaceuticals U.S.A., INC. | $155.81 | 2023-2025 | Iclusig, Fruzaqla |
| Beigene USA, INC. | $147.64 | 2023-2024 | Brukinsa |
| Daiichi Sankyo INC. | $146.92 | 2023-2024 | Enhertu, Injectafer |
| Genzyme Corporation | $136.48 | 2024 | |
| Eisai INC. | $116.41 | 2023-2024 | |
| Astellas Pharma US INC | $112.83 | 2023-2024 | Padcev, Xtandi |
| Genentech USA, INC. | $109.92 | 2023-2024 | Tecentriq, Alecensa, Rozlytrek |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $99.29 | 2023-2024 | Myrisk |
| Jazz Pharmaceuticals INC. | $92.08 | 2023-2024 | |
| Glaxosmithkline, LLC. | $87.46 | 2023-2024 | Ojjaara |
| Lilly USA, LLC | $79.78 | 2024-2025 | Verzenio, Jaypirca |
| Gilead Sciences, INC. | $79.66 | 2023-2025 | Trodelvy |
| Sobi, INC | $67.97 | 2023-2024 | |
| Servier Pharmaceuticals LLC | $64.88 | 2024-2025 | |
| Foundation Medicine, INC. | $58.61 | 2023 | Foundationone Liquid Cdx, Foundationone Cdx |
| Tersera Therapeutics LLC | $58.49 | 2024-2025 | Zoladex |
| Regeneron Healthcare Solutions, INC. | $57.39 | 2023-2024 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $52.61 | 2024 | Opdivo |
| Alexion Pharmaceuticals, INC. | $48.86 | 2024-2025 | Ultomiris |
| Incyte Corporation | $44.67 | 2025 | Zynyz, Monjuvi |
| Deciphera Pharmaceuticals INC. | $40.31 | 2023-2024 | Qinlock |
| Adc Therapeutics America, INC. | $34.22 | 2024 | |
| Dendreon Pharmaceuticals LLC | $30.81 | 2023 | Provenge |
| Geron Corporation | $29.97 | 2025 | Rytelo |
| Ucb, INC. | $29.45 | 2025 | Rystiggo |
| Stemline Therapeutics INC. | $28.84 | 2023 | Orserdu |
| Amneal Pharmaceuticals LLC | $27.23 | 2024 | Avastin |
| Eagle Pharmaceuticals, INC. | $25.38 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $20.29 | 2024 | Onivyde, Somatuline Depot |
| Abbvie INC. | $20.17 | 2024 | |
| Azurity Pharmaceuticals, INC. | $19.82 | 2024 | Vivimusta |
| Array Biopharma INC | $17.02 | 2024 | Braftovi, Tukysa, Mektovi |
| Neurelis, INC. | $16.84 | 2025 | Valtoco |
| Pharmaessentia USA Corporation | $15.93 | 2023 | Besremi |
| Shield Therapeutics INC | $14.70 | 2024 | |
| Octapharma USA, INC. | $14.13 | 2023 | Octagam Immune Globulin (Human) |
| Puma Biotechnology, INC. | $14.03 | 2023 | |
| Coherus Oncology, INC. | $13.35 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aneesha Ananthula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.